Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia

Next Previous
X
Search
Trial Profile

A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orelabrutinib (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Innocare Pharma Australia

    • Most Recent Events

    • 15 Jun 2023 Status changed from recruiting to active, no longer recruiting according to results presented at the 28th Congress of the European Haematology Association
    • 15 Jun 2023 Results assessing the efficacy, safety and tolerability oforelabrutinib in patients with persistent or chronic primary ITP presented at the 28th Congress of the European Haematology Association
    • 12 Jun 2023 According to an InnoCare Pharma media release, results from this study were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top